<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02358057</url>
  </required_header>
  <id_info>
    <org_study_id>UCL - DexAlf - 1</org_study_id>
    <nct_id>NCT02358057</nct_id>
  </id_info>
  <brief_title>Can we Get Conscious Sedation by Combining Dexmedetomidine With Alfentanil?</brief_title>
  <official_title>Can we Get Conscious Sedation in Optimal Safety Conditions in an Emergency Department, by Combining Dexmedetomidine With Alfentanil?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to determine if dexmedetomidine combine with alfentanil allow a level
      of conscious sedation within maximum security conditions in an emergency department.

      Patients included in the study will receive an injection of dexmedetomidine via a TIVA
      Injectomat Agilia, specially programmed for the injection of dexmedetomidine.

      Patients will also receive a dose of alfentanil, 1 minute before the technical act.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ramsay score scale</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Procedural Sedation</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine and Alfentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients included in the study will receive an injection of dexmedetomidine via a TIVA Injectomat Agilia, specially programmed for the injection of dexmedetomidine.
At time zero, the patient will receive a bolus 1 mcg/ kg of dexmedetomidine during 10 minutes.
Patients over 65 years will receive a bolus of 0.5 mcg/kg of dexmedetomidine during 10 minutes.
Afterwards, the patient will receive a continuous injection of 0.6 mcg/kg/h of dexmedetomidine
Patients will also receive a dose of alfentanil 1 mcg /kg, 1 minute before the technical act.
A new alfentanil dose of 0.5 mcg / kg may be injected if pain reported by the patient corresponds to an EN &gt; 50.
The maximum dose of alfentanil the patient can receive is 5 mcg / kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>Dexmedetomidine and Alfentanil</arm_group_label>
    <other_name>Dexdor</other_name>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfentanil</intervention_name>
    <arm_group_label>Dexmedetomidine and Alfentanil</arm_group_label>
    <other_name>Rapifen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult over 18 years, of both sexes, for which a procedural sedation is needed in emergency
        room. The rules for sedation, in accordance with the international guidelines, are:

          -  The insertion of a chest drain

          -  Abscess incision and drainage

          -  Closed reduction of a dislocated joint

        Exclusion Criteria:

          -  Patients refusing to participate in the study (refusal to sign the consent form)

          -  Patients refusing sedation

          -  Patients unable to participate in the study (consent is impossible to obtain)

          -  Pregnant women

          -  The hypersensitivity to the active ingredient, dexmedetomidine hydrochloride.

          -  Patients with poor respiratory status determined by:

        Respiratory rate &gt; 30 / min Oxygen saturation &lt;90%

          -  Patients with unfavorable hemodynamic status determined by :

        A heart rate &gt; 120 / min A heart rate &lt; 50 / min Systolic blood pressure ≥ 180 mmHg or
        ≤100mmHg Diastolic blood pressure ≥ 110mmHg

          -  Patients with contraindication to the use of dexmedetomidine :

        Advanced heart block (level 2 or 3) unless pacemaker Acute cerebrovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Verschuren, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Luc</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep sedation</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Emergency Service, Hospital</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Alfentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

